Search research articles
Contact Us
Filters
Showing results (31-40 of 39) with videos related to
Page
of 4
Sort By:
You have reached the last page of results.
This site can display upto 39 results.
The Journal of Organic Chemistry
|
April 23, 2024
Challenges with the Synthesis of a Macrocyclic Thioether Peptide: From Milligram to Multigram Using Solid Phase Peptide Synthesis (SPPS)
James Kempson, Rulin Zhao, Joseph Pawluczyk, et al.
Molecular Imaging and Biology
|
December 20, 2023
Development, Characterization, and Radiation Dosimetry Studies of <sup>18</sup>F-BMS-986229, a <sup>18</sup>F-Labeled PD-L1 Macrocyclic Peptide PET Tracer
Joonyoung Kim, David J Donnelly, Tritin Tran, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 14, 2018
P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor
Brian L Venables, Ny Sin, Alan Xiangdong Wang, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 4, 2023
The discovery and evaluation of [<sup>18</sup>F]BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement
David J Donnelly, Joonyoung Kim, Tritin Tran, et al.
ACS Medicinal Chemistry Letters
|
February 20, 2018
Potent Inhibitors of Hepatitis C Virus NS3 Protease: Employment of a Difluoromethyl Group as a Hydrogen-Bond Donor
Barbara Zheng, Stanley V D'Andrea, Li-Qiang Sun, et al.
Journal of Medicinal Chemistry
|
November 23, 2020
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
Li-Qiang Sun, Eric Mull, Stanley D'Andrea, et al.
Journal of Medicinal Chemistry
|
February 26, 2014
The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection
Paul M Scola, Li-Qiang Sun, Alan Xiangdong Wang, et al.
Journal of Medicinal Chemistry
|
February 22, 2014
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection
Paul M Scola, Alan Xiangdong Wang, Andrew C Good, et al.
Journal of Medicinal Chemistry
|
August 27, 2016
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing
Li-Qiang Sun, Eric Mull, Barbara Zheng, et al.
Page
of 4
Search research articles
Search
Showing results (31-40 of 39) with videos related to
Sort By:
Page
of 4
You have reached the last page of results.
This site can display upto 39 results.
The Journal of Organic Chemistry
|
April 23, 2024
Challenges with the Synthesis of a Macrocyclic Thioether Peptide: From Milligram to Multigram Using Solid Phase Peptide Synthesis (SPPS)
James Kempson, Rulin Zhao, Joseph Pawluczyk, et al.
Molecular Imaging and Biology
|
December 20, 2023
Development, Characterization, and Radiation Dosimetry Studies of <sup>18</sup>F-BMS-986229, a <sup>18</sup>F-Labeled PD-L1 Macrocyclic Peptide PET Tracer
Joonyoung Kim, David J Donnelly, Tritin Tran, et al.
Bioorganic & Medicinal Chemistry Letters
|
April 14, 2018
P3-P4 ureas and reverse carbamates as potent HCV NS3 protease inhibitors: Effective transposition of the P4 hydrogen bond donor
Brian L Venables, Ny Sin, Alan Xiangdong Wang, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 4, 2023
The discovery and evaluation of [<sup>18</sup>F]BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement
David J Donnelly, Joonyoung Kim, Tritin Tran, et al.
ACS Medicinal Chemistry Letters
|
February 20, 2018
Potent Inhibitors of Hepatitis C Virus NS3 Protease: Employment of a Difluoromethyl Group as a Hydrogen-Bond Donor
Barbara Zheng, Stanley V D'Andrea, Li-Qiang Sun, et al.
Journal of Medicinal Chemistry
|
November 23, 2020
Discovery of BMS-986144, a Third-Generation, Pan-Genotype NS3/4A Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
Li-Qiang Sun, Eric Mull, Stanley D'Andrea, et al.
Journal of Medicinal Chemistry
|
February 26, 2014
The discovery of asunaprevir (BMS-650032), an orally efficacious NS3 protease inhibitor for the treatment of hepatitis C virus infection
Paul M Scola, Li-Qiang Sun, Alan Xiangdong Wang, et al.
Journal of Medicinal Chemistry
|
February 22, 2014
Discovery and early clinical evaluation of BMS-605339, a potent and orally efficacious tripeptidic acylsulfonamide NS3 protease inhibitor for the treatment of hepatitis C virus infection
Paul M Scola, Alan Xiangdong Wang, Andrew C Good, et al.
Journal of Medicinal Chemistry
|
August 27, 2016
Discovery of a Potent Acyclic, Tripeptidic, Acyl Sulfonamide Inhibitor of Hepatitis C Virus NS3 Protease as a Back-up to Asunaprevir with the Potential for Once-Daily Dosing
Li-Qiang Sun, Eric Mull, Barbara Zheng, et al.
Page
of 4